Faculty

Carrie A. Schinstock, M.D.

Clinical Studies

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND) Rochester, Minn.
The main goal of this trial is to evaluate the efficacy of felzartamab compared to placebo in kidney transplant recipients diagnosed with late active or chronic active AMR.
Assessment of Biomarker-guided CNI substitution in Kidney Transplantation Rochester, Minn.
The purpose of the observational study is to determine the HLA-DR/DQ mMM score accurately stratifies kidney transplant recipients into low, intermediate, and high-risk categories for developing post-transplant alloimmune injury to the transplanted kidney. The HLA-DR/DQ mMM score category will prognosticate risk of developing TCMR (clinically evident and subclinical), DSA and/or ABMR in the entire study cohort: higher HLA-DR/DQ mMM score confers higher likelihood of developing TCMR, DSA and or ABMR.

The purpose of the nested RCT intervention is to determine transitioning immune quiescent kidney transplant recipients with low or intermediate HLA-DR/DQ mMM scores from a standard of care regimen to a CNI-free, abatacept-based regimen is safe and will lead to improved:

Analysis of Urinary Exosomes in Healthy Kidney Donors and Renal Transplant Recipients Rochester, Minn.
The purpose of this study is to use urinary exosomes to non-invasively identify (protein biomarkers) various conditions affecting the renal transplant.

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients (IMAGINE) Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to investigate whether clazakizumab (an anti-interleukin (IL)-6 monoclonal antibody (mAb)) may be beneficial for the treatment of CABMR in recipients of a kidney transplant by inhibiting the production of Donor Specific Antibodies (DSA) and re-shaping T cell alloimmune responses.
Alloimmune T-Cell Responses in Highly Sensitized Kidney Transplant Recipients: A Pilot Study Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to better understand how the immune system reacts to kidney transplantation in individuals who are potentially at higher risk for rejection.
Identifying Physical Function Trajectories and Biomarkers after Kidney Transplantation Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The aims of this study are to identify frailty trajectories and biomarkers of frailty after kidney transplantation. Subjects will be followed beginning immediately prior to kidney transplantation until 1 year after kidney transplantation. Frailty will be prospectively assessed using performance-based measures (Fried criteria and Short Physical Impairment Battery). The relationship between frailty measures and blood levels of promising candidate biomarkers will be analyzed.